US regulators approved gene therapies for sickle cell disease, heralding a new age of CRISPR medicine. However, the high costs may hinder widespread accessibility, impacting those in need.
While gene therapies could be life-changing for millions with sickle cell disease, prohibitive costs and logistical challenges, like multiple hospital visits, may limit their impact on improving access to treatments.
[
Collection
]
[
|
...
]